GTC Biotherapeutics (fka GTCB)

[microcapfun]

Which generics will require more thorough clinicals ...

>>The TNF-a mAbs, the recombinant plasma proteins, and the interferons (alpha and beta).<<

Only peg IF-alpha (or Albuferon or some other version of IF-alpha which has a half life of at least several days) has any chance of breaking into the market. That probably complicates things from both an equivalency and an IP perspective.

Most other protein therapeutics are also 2nd or 3rd generation, so simply copying the 1st generation version will probably not be meaningful from a market perspective.

micro